2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.071 Kenneth Samala NACLC23 Abstract

PP01.071 Kenneth Samala NACLC23 Abstract

Pdf Summary

This study examined the clinicopathologic profile of Filipino patients with advanced non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. The researchers aimed to determine the association between different clinicopathologic factors and EGFR mutation status in a tertiary hospital in the Philippines. They conducted a retrospective chart review of 82 patients with advanced NSCLC and known EGFR status. <br /><br />The results showed that 47.6% of the patients had EGFR mutations, while 52.4% did not. The patients with mutations were typically younger than 65 years old, female, non-smokers, had good performance status, had 2 or more comorbidities, and had not previously received treatment for lung cancer. The most commonly used tyrosine kinase inhibitors were gefitinib and erlotinib. Adenocarcinoma was the primary histology, and most tumors were located in the right and upper lung, with sizes ranging from 3cm to 7cm. The most common sites of metastases were pleural/pericardial effusion or bone. Tissue samples were commonly used for mutation testing, and the most frequent types of mutations were exon 19 deletion and exon 21 L858R point mutations. Gender, performance status, smoking history, and prior treatment were found to be associated with EGFR mutation status.<br /><br />These findings are consistent with previous studies that have shown a higher prevalence of EGFR mutations in female and non-smoker patients. However, this study is an initial attempt to profile EGFR mutated lung cancer patients in the Filipino population, and further research is needed to improve the understanding of this subgroup. The authors suggest that future studies should be conducted nationwide and involve multiple centers.

Keywords

Filipino patients

advanced non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR mutations

clinicopathologic profile

association

tertiary hospital

retrospective chart review

tyrosine kinase inhibitors